Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by hmmmmmmmmon Jan 06, 2025 9:00pm
180 Views
Post# 36391629

RE:RE:RE:Ten 2 go …!

RE:RE:RE:Ten 2 go …!Seto and Kellum were not clear on why 6 patients were added to their Trial's publicly disclosed tally - when those patients were not included in the trial.

I don't speak mumble, so maybe someone else can share more info on Kellum's reasoning for the counted but not enrolled.

My take away from the call was they had to disclose this issue, but did not want to explain why suddenly a group of 6 patients were missing from the trial.

He mentioned that because of the 2:1 (PMX: Control group) ratio that they may need to add not just the "missing" 6, but maybe 
9 patients to the trial. 

Again, Kellum was unclear and spoke like he didn't know what the final trial number needed to be...

So it's unknown what the final number is needed to complete the Tigris trial.  They had an obvious opportunity to clear that up in today's PR, but would rather aoid that- nearly a month after their confrence call.

Real professional show we're watching.
<< Previous
Bullboard Posts
Next >>